Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday).
Francis Crick Institute researchers, funded by Cancer Research UK, have shown that skin, breast and bowel cancer cells often produce large amounts of prostaglandin E2 (PGE2). This molecule dampens down the immune system’s normal response to attack faulty cells, which helps cancer to hide. It is a trick that allows the tumour to thrive and may explain why some immunotherapy treatments have not been as effective as hoped.
Aspirin is part of a group of molecules called COX inhibitors, which stop the production of PGE2 and help reawaken the immune system. Combining immunotherapy with aspirin or other COX inhibitors substantially slowed bowel and melanoma skin cancer growth in mice, compared to immunotherapy alone*.
Study author Professor Caetano Reis e Sousa, senior group leader at the Francis Crick Institute, said: “We’ve added to the growing evidence that some cancers produce PGE2 as a way of escaping the immune system. If you can take away cancer cells’ ability to make PGE2 you effectively lift this protective barrier and unleash the full power of the immune system.
“Giving patients COX inhibitors like aspirin at the same time as immunotherapy could potentially make a huge difference to the benefit they get from treatment. It’s still early work but this could help make cancer immunotherapy even more effective, delivering life-changing results for patients.”
Read more: Aspirin could hold the key to supercharged cancer immunotherapy
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”Cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- Component of keto diet plus immunotherapy may reduce prostate canceron April 27, 2024 at 5:21 am
Adding a pre-ketone supplement—a component of a high-fat, low-carb ketogenic diet—to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer, researchers ...
- Can cancer vaccine with immunotherapy shrink liver tumor?on April 26, 2024 at 7:30 pm
According to a study published in the journal Nature Medicine, people with Hepatocellular Carcinoma treated with immunotherapy and a personalized anti-tumor vaccine were twice as likely to experience ...
- AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Canceron April 26, 2024 at 1:59 pm
Cite this: AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer - Medscape - Apr 26, 2024.
- U.K. Tests World-First Personalized Skin Cancer Vaccineon April 26, 2024 at 9:08 am
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
- Can vitamin D help fight cancer?on April 25, 2024 at 9:45 pm
When his colleague Evangelos Giampazolias, now at the Cancer Research UK Manchester Institute, discovered that switching off the gene which provides instructions to make the aptly named vitamin ...
- Side effects of immunotherapy for cancer treatmenton April 25, 2024 at 5:31 pm
Trenton Stewart of Davenport is charged with forging checks stolen during break-in. Moline City Council endorsed the $6.8 million redevelopment proposal to convert the old JCPenny building to ...
- Merck raises 2024 profit forecast on surging sales of cancer drug Keytrudaon April 25, 2024 at 12:30 pm
Merck & Co on Thursday raised its annual profit and revenue forecast on the back of strong sales for its blockbuster cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.
- Vitamin D may balance gut microbiome to give cancer immunotherapy a booston April 25, 2024 at 12:30 pm
A new study in mice found that dietary vitamin D plays a role in balancing the gut microbiome and improving the way cancer immunotherapy works to fight tumors.
- Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlookon April 25, 2024 at 9:29 am
U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange ...
- AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'on April 23, 2024 at 3:00 am
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
via Bing News